DK1406698T3 - Lipoxinanaloger som nye inhibitorer af angiogenese - Google Patents

Lipoxinanaloger som nye inhibitorer af angiogenese

Info

Publication number
DK1406698T3
DK1406698T3 DK02721234T DK02721234T DK1406698T3 DK 1406698 T3 DK1406698 T3 DK 1406698T3 DK 02721234 T DK02721234 T DK 02721234T DK 02721234 T DK02721234 T DK 02721234T DK 1406698 T3 DK1406698 T3 DK 1406698T3
Authority
DK
Denmark
Prior art keywords
lxa
angiogenesis
novel inhibitors
lipoxin analogs
epi
Prior art date
Application number
DK02721234T
Other languages
Danish (da)
English (en)
Inventor
Iolanda M Fierro
Charles N Serhan
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK1406698T3 publication Critical patent/DK1406698T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02721234T 2001-03-02 2002-03-01 Lipoxinanaloger som nye inhibitorer af angiogenese DK1406698T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27293101P 2001-03-02 2001-03-02
PCT/US2002/006404 WO2002070068A2 (en) 2001-03-02 2002-03-01 Lipoxin analogs as novel inhibitors of angiogenesis
US10/086,609 US6627658B2 (en) 2001-03-02 2002-03-01 Lipoxin analogs as novel inhibitors of angiogenesis

Publications (1)

Publication Number Publication Date
DK1406698T3 true DK1406698T3 (da) 2009-02-09

Family

ID=26774943

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02721234T DK1406698T3 (da) 2001-03-02 2002-03-01 Lipoxinanaloger som nye inhibitorer af angiogenese

Country Status (11)

Country Link
US (4) US6627658B2 (enExample)
EP (2) EP2221089A1 (enExample)
JP (3) JP2005508282A (enExample)
AT (1) ATE412448T1 (enExample)
AU (1) AU2002252175A1 (enExample)
CY (1) CY1108670T1 (enExample)
DE (1) DE60229640D1 (enExample)
DK (1) DK1406698T3 (enExample)
ES (1) ES2316553T3 (enExample)
PT (1) PT1406698E (enExample)
WO (1) WO2002070068A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3846801A (en) 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
DK1406698T3 (da) * 2001-03-02 2009-02-09 Brigham & Womens Hospital Lipoxinanaloger som nye inhibitorer af angiogenese
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
CA2495260C (en) * 2002-08-12 2012-05-29 Brigham And Women's Hospital Resolvins: biotemplates for novel therapeutic interventions
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
WO2006052950A1 (en) * 2004-11-09 2006-05-18 Alcon, Inc. 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007061783A1 (en) * 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
US20070254897A1 (en) * 2006-04-28 2007-11-01 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
MX2009000657A (es) * 2006-07-19 2009-05-28 Resolvyx Pharmaceuticals Inc Composiciones y metodos para el tratamiento de mucositis.
US20080161274A1 (en) * 2006-10-26 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compounds and methods for inhibition of bone loss
US20080161275A1 (en) * 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
ATE528991T1 (de) * 2007-08-08 2011-11-15 Basf Se Wässrige mikroemulsionen, die organische insektizide verbindungen enthalten
WO2009038671A2 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases
KR20100080798A (ko) * 2007-10-12 2010-07-12 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
EP2219638A2 (en) * 2007-10-29 2010-08-25 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Lipoxin a4 protection for retinal cells
US7601693B2 (en) * 2008-02-05 2009-10-13 National Taiwan University Composition for treating cancer and use thereof
US20100105772A1 (en) * 2008-04-25 2010-04-29 Serhan Charles N Use of novel lipid mediators to inhibit angiogenesis
WO2014130908A1 (en) * 2013-02-22 2014-08-28 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
JP2016509863A (ja) * 2013-03-15 2016-04-04 ラーソン、マルクス カーレ、トールレイフＬＡＲＳＳＯＮ， Ｍａｒｃｕｓ Ｋａｒｅ， Ｔｏｒｌｅｉｆ 細胞、臍帯血収集のための方法及び装置、並びに細胞の単離のための方法及び装置
EP3020398A1 (en) * 2014-11-17 2016-05-18 Nitto Denko Corporation Compounds and formulations for reducing scarring
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
US11542473B2 (en) 2016-10-21 2023-01-03 Amniotics Ab Methods and compositions for generating hematopoietic cells
CN110709138A (zh) 2017-01-31 2020-01-17 布里格姆及妇女医院股份有限公司 Alx受体配体定义炎症性疾病的生化内型
WO2018161175A1 (en) * 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2020256628A1 (en) 2019-06-20 2020-12-24 Amniotics Ab An apparatus for filtering amniotic fluid
EP4234019A3 (en) 2019-10-18 2023-09-13 Amniotics AB Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
IL315234A (en) 2022-03-03 2024-10-01 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560514A (en) 1984-05-04 1985-12-24 Bengt Samuelsson Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4780281A (en) 1985-06-14 1988-10-25 Wayne State University Method for assay of peroxidase enzyme or reducing substrate activity
JPS62198677A (ja) 1986-02-26 1987-09-02 Nissan Chem Ind Ltd テトラオ−ル誘導体
JPH0739368B2 (ja) 1986-10-01 1995-05-01 旭硝子株式会社 ２０，２０，２０−トリフルオロアラキドン酸誘導体およびその製造法
CA1329809C (en) 1987-07-08 1994-05-24 Nissan Chemical Industries, Ltd. Optically active allyl alcohol and process for producing leucotriene b_ using thereof
JPH01228994A (ja) 1988-03-10 1989-09-12 Fumie Satou γ−シリルアリルアルコール及びその製造法
US5079261A (en) 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2834512B2 (ja) 1990-01-30 1998-12-09 帝人株式会社 リポキシン誘導体を有効成分とする疾患治療剤
US5322699A (en) 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JP3227922B2 (ja) 1993-01-20 2001-11-12 富士電機株式会社 自動販売機
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
PT703897E (pt) 1993-06-15 2008-11-25 Brigham & Womens Hospital Compostos de lipoxina com uma semi-vida prolongada
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US5750354A (en) 1994-03-11 1998-05-12 Brigham And Women's Hospital Lipoxin transport system and uses therefor
US6365712B1 (en) * 1996-10-25 2002-04-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
WO2000009503A1 (en) * 1998-08-13 2000-02-24 Merck & Co., Inc. Integrin receptor antagonists
DE60022327T2 (de) * 1999-03-18 2006-06-29 The Brigham And Women's Hospital Inc., Boston Lipoxinverbindungen und ihre anwendung
CA2615917C (en) * 1999-03-18 2011-10-04 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
AU3846801A (en) * 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
DK1406698T3 (da) * 2001-03-02 2009-02-09 Brigham & Womens Hospital Lipoxinanaloger som nye inhibitorer af angiogenese

Also Published As

Publication number Publication date
AU2002252175A1 (en) 2002-09-19
US20060009521A1 (en) 2006-01-12
US8008282B2 (en) 2011-08-30
US20080064749A1 (en) 2008-03-13
ATE412448T1 (de) 2008-11-15
US20020193431A1 (en) 2002-12-19
JP5302856B2 (ja) 2013-10-02
JP2012255025A (ja) 2012-12-27
DE60229640D1 (de) 2008-12-11
EP1406698B1 (en) 2008-10-29
EP2221089A1 (en) 2010-08-25
EP1406698A2 (en) 2004-04-14
WO2002070068A3 (en) 2003-12-31
CY1108670T1 (el) 2014-04-09
US6627658B2 (en) 2003-09-30
WO2002070068A2 (en) 2002-09-12
JP2010059183A (ja) 2010-03-18
PT1406698E (pt) 2009-01-12
US20040053998A1 (en) 2004-03-18
JP2005508282A (ja) 2005-03-31
ES2316553T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
DK1406698T3 (da) Lipoxinanaloger som nye inhibitorer af angiogenese
DK0650960T3 (da) Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
FI941767A0 (fi) 1H-indoli-3-asetamidi sPLA2 inhibiittoreita
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA03006248A (es) Derivados de acido fumarico como inhibidores de nf-kappab.
MY144232A (en) 5-substituted-2-phenylamino benzamides as mek inhibitors
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
EP1208092A4 (en) SULPHONAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS
NO20024237L (no) Farmasöytiske formuleringer
ES2148305T3 (es) Derivados de aminoacidos ciclicos que tienen actividad inhibidora de ace y nep.
EA200100930A1 (ru) Способ лечения хозл
YU15002A (sh) Upotreba alfa-lipoinske kiseline ili njenih derivata
DE60236467D1 (de) Lipoxinanaloge als neuartige Restenose-Hemmer
ATE352317T1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
ES2147499A1 (es) Derivados de acidos carboxilicos, metodo para su elaboracion y agentes terapeuticos que contienen estos compuestos.
ES2099894T3 (es) Derivado del acido nonatetraenoico.
EA200501083A1 (ru) Соединения, активные в ингибировании пролилолигопептидазы
SI1546083T1 (sl) Nove substituirane arilheksadienojske kisline in njihovi estri ki se lahko uporabljajo za zdravljenje in preprečevanje diabetesa dislipidemije in ateroskleroze farmacevtski sestavki ki jih vsebujejo in postopek njihove priprave
YU89903A (sh) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa